WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 461004
Description: R 115777 is a farnesyl transferase inhibitor.
MedKoo Cat#: 461004
Name: R 115777
Chemical Formula: C27H22Cl2N4O
Exact Mass: 488.1171
Molecular Weight: 489.4
Elemental Analysis: C, 66.26; H, 4.53; Cl, 14.49; N, 11.45; O, 3.27
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: R 115777; R-115777; R115777
IUPAC/Chemical Name: 2(1H)-Quinolinone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-
InChi Key: PLHJCIYEEKOWNM-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3
SMILES Code: O=C1N(C)C2=C(C=C(C(C3=CC=C(Cl)C=C3)(N)C4=CN=CN4C)C=C2)C(C5=CC=CC(Cl)=C5)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 489.4 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar;16(3):381-92. Review. PubMed PMID: 17302532.
2: Lavelle F. American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania. Expert Opin Investig Drugs. 1999 Jun;8(6):903-9. PubMed PMID: 15992139.
3: Lavelle F. American Association for Cancer Research 1998: promises and prospects for the next century. Expert Opin Investig Drugs. 1998 Jun;7(6):1015-21. PubMed PMID: 15992013.
4: Morgan MA, Ganser A, Reuter CW. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia. 2003 Aug;17(8):1482-98. Review. PubMed PMID: 12886235.
5: R-115777. Drug News Perspect. 2000 Dec;13(10):621. PubMed PMID: 12879132.
6: Dempke WC. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res. 2003 Mar-Apr;23(2A):813-8. Review. PubMed PMID: 12820305.
7: Haller DG. Future directions in the treatment of pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 20):31-9. Review. PubMed PMID: 12577231.
8: Singh SB, Lingham RB. Current progress on farnesyl protein transferase inhibitors. Curr Opin Drug Discov Devel. 2002 Mar;5(2):225-44. Review. PubMed PMID: 11926129.